Yakuchinone B
Based on 1 Customer Validation
Yakuchinone B is an orally active and potent 5-LOX and COX-1/2 inhibitor with IC50 values of 0.37, 53.9, and 42 μM, respectively, and can be isolated and extracted from Alpinia oxyphylla. Yakuchinone B exhibits anti-inflammatory, antioxidant, and antitumor activities. Yakuchinone B exerts anti-inflammatory protective effects by inhibiting 5-LOX/COX activity and AP-1 DNA binding, downregulating the expression of pro-inflammatory factors, and modulating the gut microbiota metabolic axis to promote short-chain fatty acid production. Yakuchinone B can be used for research on colitis and cancer.
For research use only. We do not sell to patients.
- Purity : 99.58%
- CAS No.: 81840-57-5
- Formula: C20H22O3
- Molecular Weight:310.39
-
Storage:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Biological Activity
Description
|
5-LOX 0.37 μM (IC50) |
Ovine COX-1 53.9 μM (IC50) |
Ovine COX-2 42 μM (IC50) |
TNF-α |
In Vitro
Yakuchinone B (50-100 µM; pretreatment for 30 min, co-treatment for 12 h) inhibits TNF-α production in TPA (HY-18739)-stimulated HL-60 cells[4].
Yakuchinone B (10-100 μM; 10 min pretreatment, 30 min TPA stimulation) attenuates TPA-induced superoxide anion production in differentiated HL-60 cells[4].
Yakuchinone B (0.5-10 μM; 20 min) inhibits lipid peroxidation in rat brain homogenates[4].
Yakuchinone B (0.01-100 μM; 15 min) inhibits 5-LOX activity in RBL-1 cell lysate supernatant with an IC50 of 0.37 µM[2].
Yakuchinone B (0.01-100 μM; preincubation for 10 min followed by co-incubation with 0.5 µM A23187 for 10 min) inhibits A23187 (HY-N6687)-induced production of LTB4 and LTC4 in RBL-1 cells, with IC50 values of 0.49 µM and 0.61 µM, respectively[2].
Yakuchinone B inhibits COX-1 and COX-2 activity in sheep seminal vesicle microsomes and the activity of sheep placental COX-2 preparations, with IC50 values of 53.9 µM and 42.0 µM, respectively[2].
Yakuchinone B (1-100 μM; pre-incubation for 2 h; co-incubation for 6 h) inhibits the adhesion of U937 monocytes and EoL-1 eosinophils to TNF-α (HY-P7058)-treated HUVECs[3].
Yakuchinone B (1-100 μM; pretreatment for 2 h, co-treatment with TNF-α or IL-1β for 6 h or 8 h) inhibits the expression of the cell surface adhesion molecules E-selectin, VCAM-1, and ICAM-1 in TNF-α- or IL-1β (HY-P78459)-treated HUVECs[3].
Yakuchinone B (100 μM; pretreatment for 30 min, TPA stimulation for 1 h) inhibits transcription factor AP-1 binding to DNA (AP-1 activation) in NIH3T3 cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:TNF-α- or IL-1β-treated human umbilical vein endothelial cells (HUVEC)
-
Concentration:1, 10, 30, 50, 100 μM
-
Incubation Time:pre-treated for 2 h, co-treated with TNF-α or IL-1β for 6 hours or 8 h
-
Result:Significantly suppressed the TNF-α- or IL-1β-induced cell surface expression of E-selectin, VCAM-1, and ICAM-1 in endothelial cells
-
Cell Line:human promyelocytic leukemia HL-60 cells
-
Concentration:50, 100 µM
-
Incubation Time:pre-treated for 30 min, followed by 12 h of treatment
-
Result:Significantly inhibited the massive production of TNF-α stimulated by TPA.
In Vivo
Yakuchinone B (50 μmol; t.d.; single administration; 5.5 h) inhibits epidermal ornithine decarboxylase (ODC) activity in a TPA-induced epidermal ornithine decarboxylase activation ICR mouse model[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CD-1 (male)[6]
-
Dosage:100 mg/kg, 200 mg/kg
-
Administration:i.g.; once daily; days 7-21
-
Result:Significantly attenuated DSS-induced body weight loss, elevated disease activity index (DAI), colonic shortening, and splenomegaly.
Ameliorated histopathological mucosal damage in the colon and reduced inflammatory cell infiltration.
Decreased the levels of TNF-α, IL-1β, and IL-6 in colonic tissues and serum.
Restored gut microbial diversity, increased the abundances of Alistipes and Duncaniella, and suppressed the overgrowth of Akkermansia.
Promoted the production of short-chain fatty acids (acetic acid, propionic acid, and butyric acid) in the cecum.
Modulated host metabolic pathways, including purine metabolism, amino acid metabolism, and steroid hormone biosynthesis.
Chemical Information
-
CAS No. 81840-57-5
-
Appearance Solid
-
Molecular Weight 310.39
-
Formula C20H22O3
-
Color Off-white to light yellow
-
SMILES
O=C(CCCCC1=CC=CC=C1)/C=C/C2=CC(OC)=C(C=C2)O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Protocols
-
Protocol for Electrophoretic Mobility Shift Assay (EMSA)
Electrophoretic mobility shift assay detects protein-nucleic acid binding by incubating a labeled DNA or RNA probe with purified protein or cell extract, then separating free probe from slower-migrating protein-probe complexes on a native gel. For cancer cells, primary neurons, mouse tumor samples, intestinal organoids, inflammatory macrophages, or drug-treated samples, EMSA can measure transcription-factor DNA binding or RNA-binding protein activity in extracts, but it does not directly measure transcription, protein expression, or chromatin occupancy in intact cells. Specificity is judged by competition with unlabeled wild-type probe, failure of mutated or unrelated competitors to compete, and antibody supershift or disruption when the binding protein identity must be confirmed.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
DSS-Induced Colitis
Dextran sulfate sodium (DSS)-induced colitis is generated by administering DSS in mouse drinking water, producing epithelial injury, barrier disruption, weight loss, diarrhea, fecal blood, colon shortening, histologic mucosal damage, and inflammatory mediator changes; the model is mainly used to study acute or chronic intestinal inflammation resembling selected features of ulcerative colitis. DSS injury is interpreted through clinical and tissue readouts rather than a single molecular endpoint: daily body weight, stool consistency, and bleeding are combined into a disease activity index, while colon length, histology, cytokines, myeloperoxidase activity, intestinal permeability, and tight-junction markers provide complementary measures of inflammation and barrier damage.
-
TNBS-Induced Colitis
TNBS-induced colitis is produced by intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid in ethanol, where ethanol disrupts the mucosal barrier and TNBS haptenates colonic proteins, generating immune-mediated colonic inflammation with weight loss, diarrhea, ulceration, transmural injury, inflammatory-cell infiltration, and cytokine responses. The model is used as an experimental intestinal inflammation model with Crohn’s disease–like features, especially when Th1-type responses, IL-12–dependent inflammation, chronic relapsing inflammation, or fibrosis-related endpoints are studied.
-
Research Protocol for Microbiome Analysis
Microbiome analysis characterizes microbial communities in biological or environmental samples by measuring community composition, diversity, taxonomic structure, functional potential, and associations with host or environmental phenotypes. 16S rRNA gene amplicon sequencing is commonly used for bacterial and archaeal taxonomic profiling, while shotgun metagenomics provides higher taxonomic resolution and direct functional information, including microbial genes, pathways, viruses, fungi, and antimicrobial-resistance genes when sequencing depth and host-DNA contamination are adequately controlled. Microbiome results are strongly affected by sample collection, storage, DNA extraction, contamination, sequencing method, reference database, and bioinformatic pipeline; therefore, standardized protocols, negative controls, mock communities, and transparent analysis workflows are required. Unresolved issues include low-biomass contamination, compositional-data bias, inconsistent species-level c
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)